A Single-arm Open-label Clinical Trial of Autologous Epidermal Cell Transplantation for Stable Vitiligo: A 30-month Follow-Up

Vitiligo is a common pigmentation disorder with a worldwide prevalence of 0.4%–2% [1] characterized by white patches on the skin and mucus membrane [2]. The disease negatively impacts on the patients' quality of life, psychological health and social activities [2,3]. Various therapies are available for vitiligo including local or systemic immunosuppressive drugs, light-based and surgical therapies. However, all the patients do not show satisfactory response to the current treatments [4–7].